ecrin-mdr-crcClinical2018Metastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2328450China5IrinotecanCapecitabineXELIRIFluorouracilBevacizumabFOLFIRIECRIN MDRCompletedfalseA Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal CancerThis is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin) plus mXELIRI compared with bevacizumab (Avastin) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).2018-05-152328450NCT04247984